Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 29.12% is 408% above its 5-year average of -9.45%, near the high end of its 5-year range (-53.94%–31.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.66% below its 12-month average of 29.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 29.12%.
RETURN ON EQUITY (ROE)
29.12%
RETURN ON EQUITY (ROE) AVG TTM
29.31%
RETURN ON EQUITY (ROE) AVG 3Y
11.69%
RETURN ON EQUITY (ROE) AVG 5Y
-9.45%
RETURN ON EQUITY (ROE) AVG 10Y
-32.15%
RETURN ON EQUITY (ROE) AVG 15Y
-33.62%
RETURN ON EQUITY (ROE) AVG 20Y
-38.04%
CURRENT VS TTM AVG
-0.66%
CURRENT VS 3Y AVG
+149.21%
CURRENT VS 5Y AVG
+408.04%
CURRENT VS 10Y AVG
+190.58%
CURRENT VS 15Y AVG
+186.62%
CURRENT VS 20Y AVG
+176.55%
SECTOR MEDIAN · HEALTHCARE
-30.74%
median of 343 covered companies
CURRENT VS SECTOR MEDIAN
+194.73%
vs the sector median at left
Acadia Pharmaceuticals Inc.
Market Cap
$3.44B
Return on Equity (ROE)
29.12%
TTM Avg
29.31%
3Y Avg
11.69%
5Y Avg
-9.45%
Market Cap
$3.59B
Return on Equity (ROE)
N/A
TTM Avg
-136.37%
3Y Avg
-87.14%
5Y Avg
-78.77%
Market Cap
$3.61B
Return on Equity (ROE)
26.08%
TTM Avg
3.42%
3Y Avg
-20.94%
5Y Avg
-16.18%
Market Cap
$3.25B
Return on Equity (ROE)
-11.83%
TTM Avg
-25.64%
3Y Avg
-7.84%
5Y Avg
-12.83%
Market Cap
$3.16B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
Market Cap
$3.15B
Return on Equity (ROE)
12.93%
TTM Avg
-48.70%
3Y Avg
-135.42%
5Y Avg
-110.19%
Market Cap
$3.09B
Return on Equity (ROE)
-63.59%
TTM Avg
-115.27%
3Y Avg
-69.35%
5Y Avg
-25.98%
Market Cap
$2.88B
Return on Equity (ROE)
-73.97%
TTM Avg
-48.15%
3Y Avg
-105.34%
5Y Avg
-79.84%
Market Cap
$2.87B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc. (ACAD) | $3.44B | 29.12% | 29.31% | 11.69% | -9.45% |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A | -136.37% | -87.14% | -78.77% |
| CareDx, Inc (CDNA)vs › | $3.61B | 26.08% | 3.42% | -20.94% | -16.18% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | -11.83% | -25.64% | -7.84% | -12.83% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -61.24% | -42.47% | -32.58% | -25.72% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 12.93% | -48.70% | -135.42% | -110.19% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -63.59% | -115.27% | -69.35% | -25.98% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -73.97% | -48.15% | -105.34% | -79.84% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 29.28% | 27.86% | 4.54% | -12.45% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 2.04% | -6.01% | -7.18% | -5.00% |
ROE
29.1%
ROA
21.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 29.12% |
| 2026-03-31 | 30.10% |
| 2025-12-31 | 31.86% |
| 2025-09-30 | 28.47% |
| 2025-06-30 | 27.01% |
| 2025-03-31 | 29.91% |
| 2024-12-31 | 30.90% |
| 2024-09-30 | 22.26% |
| 2024-06-30 | 5.92% |
| 2024-03-31 | -0.37% |
| 2023-12-31 | -14.19% |
| 2023-09-30 | -41.09% |
| 2023-06-30 | -28.00% |
| 2023-03-31 | -38.99% |
| 2022-12-31 | -53.94% |
| 2022-09-30 | -51.06% |
| 2022-06-30 | -47.06% |
| 2022-03-31 | -48.22% |
| 2021-12-31 | -31.04% |
| 2021-09-30 | -33.78% |
| 2021-06-30 | -46.34% |
| 2021-03-31 | -44.71% |
| 2020-12-31 | -44.91% |
| 2020-09-30 | -40.90% |
| 2020-06-30 | -33.96% |
| 2020-03-31 | -37.28% |
| 2019-12-31 | -33.65% |
| 2019-09-30 | -35.94% |
| 2019-06-30 | -68.88% |
| 2019-03-31 | -66.02% |
| 2018-12-31 | -51.18% |
| 2018-09-30 | -111.25% |
| 2018-06-30 | -95.07% |
| 2018-03-31 | -84.12% |
| 2017-12-31 | -86.32% |
| 2017-09-30 | -79.30% |
| 2017-06-30 | -73.61% |
| 2017-03-31 | -67.64% |
| 2016-12-31 | -52.35% |
| 2016-09-30 | -41.26% |
| 2016-06-30 | -50.33% |
| 2016-03-31 | -39.04% |
| 2015-12-31 | -82.32% |
| 2015-09-30 | -64.67% |
| 2015-06-30 | -51.95% |
| 2015-03-31 | -40.35% |
| 2014-12-31 | -29.88% |
| 2014-09-30 | -23.04% |
| 2014-06-30 | -17.73% |
| 2014-03-31 | -13.59% |
| 2013-12-31 | -20.84% |
| 2013-09-30 | -18.10% |
| 2013-06-30 | -13.45% |
| 2013-03-31 | -26.05% |
| 2012-12-31 | -24.53% |
| 2012-09-30 | -109.48% |
| 2012-06-30 | -173.22% |
| 2012-03-31 | -131.65% |
| 2011-12-31 | -97.44% |
| 2011-09-30 | 41.49% |
| 2011-06-30 | 38.16% |
| 2011-03-31 | 38.82% |
| 2010-12-31 | 50.99% |
| 2010-06-30 | -861.60% |
| 2010-03-31 | -502.00% |
| 2009-12-31 | -372.68% |
| 2009-09-30 | -265.83% |
| 2009-06-30 | -216.96% |
| 2009-03-31 | -163.77% |
| 2008-12-31 | -121.23% |
| 2008-09-30 | -101.63% |
| 2008-06-30 | -83.43% |
| 2008-03-31 | -61.03% |
| 2007-12-31 | -49.49% |
| 2007-09-30 | -39.93% |
| 2007-06-30 | -32.59% |
| 2007-03-31 | -84.75% |
| 2006-12-31 | -67.08% |
| 2006-09-30 | -54.59% |
| 2006-06-30 | -49.51% |
| 2006-03-31 | -95.37% |
| 2005-12-31 | -86.70% |
| 2005-09-30 | -63.55% |
| 2005-06-30 | -41.17% |
| 2005-03-31 | -77.31% |
| 2004-12-31 | -84.47% |
| 2004-09-30 | -59.17% |
| 2004-06-30 | -45.37% |
